Hepatitis B Virus: From Diagnosis to Treatment

Abdul Basit S, Dawood A, Ryan J, Gish R. Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. Expert Rev Clin Pharmacol. 2017 Jul 03;10(7):707–716. https://doi.org/10.1080/17512433.2017.1323633Abdul BasitSDawoodARyanJGishR. Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. Expert Rev Clin Pharmacol.2017Jul 03;10(7):707–716. https://doi.org/10.1080/17512433.2017.132363310.1080/17512433.2017.132363328460547Search in Google Scholar

Agarwal K, Fung SK, Nguyen TT, Cheng W, Sicard E, Ryder SD, Flaherty JF, Lawson E, Zhao S, Subramanian GM, et al. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol. 2015 Mar;62(3):533–540. https://doi.org/10.1016/j.jhep.2014.10.035AgarwalKFungSKNguyenTTChengWSicardERyderSDFlahertyJFLawsonEZhaoSSubramanianGMTwenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.J Hepatol.2015Mar;62(3):533–540. https://doi.org/10.1016/j.jhep.2014.10.03510.1016/j.jhep.2014.10.03525450717Search in Google Scholar

Aghasadeghi MR, Aghakhani A, Mamishi S, Bidari-Zerehpoosh F, Haghi Ashtiani MT, Sabeti S, Banifazl M, Karami A, Bavand A, Ramezani A. No evidence of occult HBV infection in population born after mass vaccination. Wien Med Wochenschr. 2020 Jun; 170(9–10):218–223. https://doi.org/10.1007/s10354-020-00748-zAghasadeghiMRAghakhaniAMamishiSBidari-ZerehpooshFHaghi AshtianiMTSabetiSBanifazlMKaramiABavandARamezaniA. No evidence of occult HBV infection in population born after mass vaccination. Wien Med Wochenschr.2020Jun; 170(9–10):218–223. https://doi.org/10.1007/s10354-020-00748-z10.1007/s10354-020-00748-z32274600Search in Google Scholar

Al-Qahtani AA, Al-Anazi MR, Nazir N, Abdo AA, Sanai FM, Al-Hamoudi WK, Alswat KA, Al-Ashgar HI, Khan MQ, Albenmousa A, et al. The correlation between hepatitis B virus Precore/core mutations and the progression of severe liver disease. Front Cell Infect Microbiol. 2018 Oct 22;8:355. https://doi.org/10.3389/fcimb.2018.00355Al-QahtaniAAAl-AnaziMRNazirNAbdoAASanaiFMAl-HamoudiWKAlswatKAAl-AshgarHIKhanMQAlbenmousaAThe correlation between hepatitis B virus Precore/core mutations and the progression of severe liver disease.Front Cell Infect Microbiol.2018Oct 22;8:355. https://doi.org/10.3389/fcimb.2018.0035510.3389/fcimb.2018.00355620445930406036Search in Google Scholar

Al-Sadeq DW, Taleb SA, Zaied RE, Fahad SM, Smatti MK, Rizeq BR, Al Thani AA, Yassine HM, Nasrallah GK. Hepatitis B virus molecular epidemiology, host virus interaction, co infection, and laboratory diagnosis in the MENA Region: an Update. Pathogens. 2019 May 11;8(2):63. https://doi.org/10.3390/pathogens8020063Al-SadeqDWTalebSAZaiedREFahadSMSmattiMKRizeqBRAl ThaniAAYassineHMNasrallahGK. Hepatitis B virus molecular epidemiology, host virus interaction, co infection, and laboratory diagnosis in the MENA Region: an Update. Pathogens.2019May 11;8(2):63. https://doi.org/10.3390/pathogens802006310.3390/pathogens8020063663067131083509Search in Google Scholar

Ambachew H, Zheng M, Pappoe F, Shen J, Xu Y. Genotyping and sero-virological characterization of hepatitis B virus (HBV) in blood donors, Southern Ethiopia. PLoS One. 2018 Feb 20;13(2):e0193177. https://doi.org/10.1371/journal.pone.0193177AmbachewHZhengMPappoeFShenJXuY. Genotyping and sero-virological characterization of hepatitis B virus (HBV) in blood donors, Southern Ethiopia. PLoS One.2018Feb 20;13(2):e0193177. https://doi.org/10.1371/journal.pone.019317710.1371/journal.pone.0193177581982029462187Search in Google Scholar

Arikan A, Şanlidağ T, Süer K, Sayan M, Akçali S, Güler E. [Molecular epidemiology of hepatitis B virus in Northern Cyprus] (in Turkish). Mikrobiyol Bul. 2016 Jan 7;50(1):86–93. https://doi.org/10.5578/mb.10292ArikanAŞanlidağTSüerKSayanMAkçaliSGülerE. [Molecular epidemiology of hepatitis B virus in Northern Cyprus] (in Turkish). Mikrobiyol Bul.2016Jan 7;50(1):86–93. https://doi.org/10.5578/mb.1029210.5578/mb.1029227058332Search in Google Scholar

Arikan A, Sayan M, Sanlidag T, Suer K, Akcali S, Guvenir M. Evaluation of the pol/S gene overlapping mutations in chronic hepatitis B patients in Northern Cyprus. Pol J Microbiol. 2019 Sep; 68(3):317–322. https://doi.org/10.33073/pjm-2019-034ArikanASayanMSanlidagTSuerKAkcaliSGuvenirM. Evaluation of the pol/S gene overlapping mutations in chronic hepatitis B patients in Northern Cyprus. Pol J Microbiol.2019Sep; 68(3):317–322. https://doi.org/10.33073/pjm-2019-03410.33073/pjm-2019-034725683431880877Search in Google Scholar

Arikan A, Sayan M. Comparison of Qiagen and Iontek hepatitis B virus DNA polymerase chain reaction quantification kits in chronic hepatitis B patients infected with hepatitis B genotype D. Viral Hepat J. 2020 Apr 28;26(1):9–13. https://doi.org/10.4274/vhd.galenos.2020.2019.0024ArikanASayanM. Comparison of Qiagen and Iontek hepatitis B virus DNA polymerase chain reaction quantification kits in chronic hepatitis B patients infected with hepatitis B genotype D. Viral Hepat J.2020Apr 28;26(1):9–13. https://doi.org/10.4274/vhd.galenos.2020.2019.002410.4274/vhd.galenos.2020.2019.0024Search in Google Scholar

CDC. Interpretation of hepatitis B serological test results [Internet]. Atlanta (USA): Centers for Disease Control and Prevention; 2005 [cited 2020]. Available from https://www.cdc.gov/HEPATITIS/HBV/PDFs/SerologicChartv8.pdfCDC. Interpretation of hepatitis B serological test results [Internet]. Atlanta (USA): Centers for Disease Control and Prevention; 2005[cited 2020]. Available from https://www.cdc.gov/HEPATITIS/HBV/PDFs/SerologicChartv8.pdfSearch in Google Scholar

CDC. Morbidity and mortality weekly report recommendations and report. Centers for Disease Control and Prevention. 2018;67(1):1–32.CDC. Morbidity and mortality weekly report recommendations and report. Centers for Disease Control and Prevention.2018;67(1):1–32.Search in Google Scholar

CDC. Interpretation of hepatitis B serological tests results [Internet]. Atlanta (USA): Centers for Disease Control and Prevention; 2020a [cited 2020 Mar]. Available from https://www.cdc.gov/hepatitis/hbv/index.htmCDC. Interpretation of hepatitis B serological tests results [Internet]. Atlanta (USA): Centers for Disease Control and Prevention; 2020a[cited 2020 Mar]. Available from https://www.cdc.gov/hepatitis/hbv/index.htmSearch in Google Scholar

CDC. Hepatitis B questions and answers for public health professionals [Internet]. Atlanta (USA): Centers for Disease Control and Prevention; 2020b [cited 2020 Mar]. Available from https://www.cdc.gov/hepatitis/hbv/hbvfaq.htmCDC. Hepatitis B questions and answers for public health professionals [Internet]. Atlanta (USA): Centers for Disease Control and Prevention; 2020b[cited 2020 Mar]. Available from https://www.cdc.gov/hepatitis/hbv/hbvfaq.htmSearch in Google Scholar

CDC. Immunization schedules [Internet]. Atlanta (USA): Centers for Disease Control and Prevention; 2020c [cited 2020 Feb]. Available from https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent. html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccin es%2Fschedules%2Fhcp%2Fchild-adolescent.htmlCDC. Immunization schedules [Internet]. Atlanta (USA): Centers for Disease Control and Prevention; 2020c[cited 2020 Feb]. Available from https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent. html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccin es%2Fschedules%2Fhcp%2Fchild-adolescent.htmlSearch in Google Scholar

CDC. Interpretation of hepatitis B serological Tests results [Internet]. Atlanta (USA): Centers for Disease Control and Prevention; 2020d [cited 2020 Mar]. Available from https://www.cdc.gov/hepatitis/hbv/index.htmCDC. Interpretation of hepatitis B serological Tests results [Internet]. Atlanta (USA): Centers for Disease Control and Prevention; 2020d[cited 2020 Mar]. Available from https://www.cdc.gov/hepatitis/hbv/index.htmSearch in Google Scholar

Chan HL, Wang H, Niu J, Chim AM, Sung JJ. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther. 2007;12(3): 345–353.ChanHLWangHNiuJChimAMSungJJ. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther.2007;12(3): 345–353.10.1177/135965350701200308Search in Google Scholar

Cholongitas E, Haidich AB, Apostolidou-Kiouti F, Chalevas P, Papatheodoridis GV. Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review. Ann Gastroenterol. 2018;31(4):480–490. https://doi.org/10.20524/aog.2018.0266CholongitasEHaidichABApostolidou-KioutiFChalevasPPapatheodoridisGV. Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review. Ann Gastroenterol.2018;31(4):480–490. https://doi.org/10.20524/aog.2018.026610.20524/aog.2018.0266603376729991894Search in Google Scholar

Cooksley WGE, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, Chutaputti A, Chang WY, Zahm FE, Pluck N. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat. 2003 Jul;10(4):298–305. https://doi.org/10.1046/j.1365-2893.2003.00450.xCooksleyWGEPiratvisuthTLeeSDMahachaiVChaoYCTanwandeeTChutaputtiAChangWYZahmFEPluckN. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.J Viral Hepat.2003Jul;10(4):298–305. https://doi.org/10.1046/j.1365-2893.2003.00450.x10.1046/j.1365-2893.2003.00450.x12823597Search in Google Scholar

de Almeida RW, Espírito-Santo MP, Sousa PSF, de Almeida AJ, Lampe E, Lewis-Ximenez LL. Hepatitis B virus DNA stability in plasma samples under short-term storage at 42°C. Braz J Med Biol Res. 2015 Jun;48(6):553–556. https://doi.org/10.1590/1414-431x20144040de AlmeidaRWEspírito-SantoMPSousaPSFde AlmeidaAJLampeELewis-XimenezLL. Hepatitis B virus DNA stability in plasma samples under short-term storage at 42°C. Braz J Med Biol Res.2015Jun;48(6):553–556. https://doi.org/10.1590/1414-431x2014404010.1590/1414-431x20144040447031525790101Search in Google Scholar

Dini G, Toletone A, Barberis I, Debarbieri N, Massa E, Paganino C, Bersi F, Montecucco A, Alicino C, Durando P. Persistence of protective anti-HBs antibody levels and anamnestic response to HBV booster vaccination: A cross-sectional study among healthcare students 20 years following the universal immunization campaign in Italy. Hum Vaccin Immunother. 2017 Feb;13(2):440–444. https://doi.org/10.1080/21645515.2017.1264788DiniGToletoneABarberisIDebarbieriNMassaEPaganinoCBersiFMontecuccoAAlicinoCDurandoP. Persistence of protective anti-HBs antibody levels and anamnestic response to HBV booster vaccination: A cross-sectional study among healthcare students 20 years following the universal immunization campaign in Italy. Hum Vaccin Immunother.2017Feb;13(2):440–444. https://doi.org/10.1080/21645515.2017.126478810.1080/21645515.2017.1264788532821627925503Search in Google Scholar

Dynavax. Hepatitis B Recombinant vaccine [Internet]. 2018 [cited 2018 Feb]. Available from https://investors.dynavax.com/static-files/f93ec0ea-c184-4afb-b2d6-98ebd0030a79Dynavax. Hepatitis B Recombinant vaccine [Internet]. 2018[cited 2018 Feb]. Available from https://investors.dynavax.com/static-files/f93ec0ea-c184-4afb-b2d6-98ebd0030a79Search in Google Scholar

EASL. HBV 2017 Clinical practice guidelines on the management of hepatitis B virus infection [Internet]. Geneva (Switzerland): European Association for the Study of the Liver; 2017 [cited 2020 Mar]. Available from https://easl.eu/wp-content/uploads/2018/10/HepB-English-report.pdfEASL. HBV 2017 Clinical practice guidelines on the management of hepatitis B virus infection [Internet]. Geneva (Switzerland): European Association for the Study of the Liver; 2017[cited 2020 Mar]. Available from https://easl.eu/wp-content/uploads/2018/10/HepB-English-report.pdfSearch in Google Scholar

FDA. Hepatitis B [Internet]. Silver Spring (USA): Food and Drug Administration; 2019 [cited 2019 Apr 9]. Available from https://www. fda.gov/vaccines-blood-biologics/blood-donor-screening/hepatitis-bFDA. Hepatitis B [Internet]. Silver Spring (USA): Food and Drug Administration; 2019[cited 2019 Apr 9]. Available from https://www. fda.gov/vaccines-blood-biologics/blood-donor-screening/hepatitis-bSearch in Google Scholar

Fletcher GJ, Eapen CE, Abraham P. Hepatitis B genotyping: the utility for the clinicians. Indian J Gastroenterol. 2019 Oct 15;39(4): 315–320. https://doi.org/10.1007/s12664-019-00995-yFletcherGJEapenCEAbrahamP. Hepatitis B genotyping: the utility for the clinicians. Indian J Gastroenterol.2019Oct 15;39(4): 315–320. https://doi.org/10.1007/s12664-019-00995-y10.1007/s12664-019-00995-y31617082Search in Google Scholar

Ganczak M, Topczewska K, Budnik-Szymoniuk M, Korzeń M. Seroprevalence of anti-HBc, risk factors of occupationally acquired HBV infection and HBV vaccination among hospital staff in Poland: a multicenter study. BMC Public Health. 2019 Dec;19(1):298. https://doi.org/10.1186/s12889-019-6628-1GanczakMTopczewskaKBudnik-SzymoniukMKorzeńM. Seroprevalence of anti-HBc, risk factors of occupationally acquired HBV infection and HBV vaccination among hospital staff in Poland: a multicenter study. BMC Public Health.2019Dec;19(1):298. https://doi.org/10.1186/s12889-019-6628-110.1186/s12889-019-6628-1641712830866893Search in Google Scholar

Gilead Sciences. Prescribing information: VEMLIDY® (tenofovir alafenamide) [Internet]. Foster City (USA): Gilead Sciences; 2015 [cited 2020 Sep]. Available from https://www.gilead.com/-/media/files/pdfs/medicines/liver-disease/vemlidy/vemlidy_pi.pdfGilead Sciences. Prescribing information: VEMLIDY® (tenofovir alafenamide) [Internet]. Foster City (USA): Gilead Sciences; 2015[cited 2020 Sep]. Available from https://www.gilead.com/-/media/files/pdfs/medicines/liver-disease/vemlidy/vemlidy_pi.pdfSearch in Google Scholar

Gilman C, Heller T, Koh C. Chronic hepatitis delta: A state-of-the-art review and new therapies. World J Gastroenterol. 2019 Aug 28; 25(32):4580–4597. https://doi.org/10.3748/wjg.v25.i32.4580GilmanCHellerTKohC. Chronic hepatitis delta: A state-of-the-art review and new therapies. World J Gastroenterol.2019Aug 28; 25(32):4580–4597. https://doi.org/10.3748/wjg.v25.i32.458010.3748/wjg.v25.i32.4580671803431528088Search in Google Scholar

HBF. About the Hepatitis B Foundation. Doylestown (USA): Hepatitis B Foundation; 2018a [cited 2020 Sep 3]. Available from https://www.hepb.org/assets/Uploads/About-the-Hepatitis-B-Foundation-Fact-Sheet-final-8-28-18.pdfHBF. About the Hepatitis B Foundation. Doylestown (USA): Hepatitis B Foundation; 2018a[cited 2020 Sep 3]. Available from https://www.hepb.org/assets/Uploads/About-the-Hepatitis-B-Foundation-Fact-Sheet-final-8-28-18.pdfSearch in Google Scholar

HBF. Hepatitis B test [Internet]. Doylestown (USA): Hepatitis B Foundation; 2018b [cited 2020 Sep 3]. Available from https://www. hepb.org/prevention-and-diagnosis/diagnosis/hbv-blood-testsHBF. Hepatitis B test [Internet]. Doylestown (USA): Hepatitis B Foundation; 2018b[cited 2020 Sep 3]. Available from https://www. hepb.org/prevention-and-diagnosis/diagnosis/hbv-blood-testsSearch in Google Scholar

Ho EY, Yau T, Rousseau F, Heathcote EJ, Lau GKK. Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy. Hepatol Int. 2015 Apr;9(2):224–230. https://doi.org/10.1007/s12072-015-9612-6HoEYYauTRousseauFHeathcoteEJLauGKK. Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy. Hepatol Int.2015Apr;9(2):224–230. https://doi.org/10.1007/s12072-015-9612-610.1007/s12072-015-9612-625788197Search in Google Scholar

Huang D, Lin T, Wang S, Cheng L, Xie L, Lu Y, Chen M, Zhu L, Shi J. The liver fibrosis index is superior to the APRI and FIB-4 for predicting liver fibrosis in chronic hepatitis B patients in China. BMC Infect Dis. 2019 Dec;19(1):878. https://doi.org/10.1186/s12879-019-4459-4HuangDLinTWangSChengLXieLLuYChenMZhuLShiJ. The liver fibrosis index is superior to the APRI and FIB-4 for predicting liver fibrosis in chronic hepatitis B patients in China. BMC Infect Dis.2019Dec;19(1):878. https://doi.org/10.1186/s12879-019-4459-410.1186/s12879-019-4459-4680558031640590Search in Google Scholar

Hyun Kim B, Ray Kim W. Epidemiology of hepatitis B virus infection in the United States. Clin Liver Dis (Hoboken). 2018 Jul;12(1): 1–4. https://doi.org/10.1002/cld.732Hyun KimBRay KimW. Epidemiology of hepatitis B virus infection in the United States.Clin Liver Dis (Hoboken).2018Jul;12(1): 1–4. https://doi.org/10.1002/cld.73210.1002/cld.732638590230988901Search in Google Scholar

Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother. 1997 Jul;41(7):1444–1448. https://doi.org/10.1128/AAC.41.7.1444InnaimoSFSeiferMBisacchiGSStandringDNZahlerRColonnoRJ. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother.1997Jul;41(7):1444–1448. https://doi.org/10.1128/AAC.41.7.144410.1128/AAC.41.7.14441639379210663Search in Google Scholar

Jackson K, Locarnini S, Gish R. Diagnostics of Hepatitis B virus: standard of care and investigational. Clin Liver Dis (Hoboken). 2018 Jul;12(1):5–11. https://doi.org/10.1002/cld.729JacksonKLocarniniSGishR. Diagnostics of Hepatitis B virus: standard of care and investigational.Clin Liver Dis (Hoboken).2018Jul;12(1):5–11. https://doi.org/10.1002/cld.72910.1002/cld.729638590430988902Search in Google Scholar

Jefferies M, Rauff B, Rashid H, Lam T, Rafiq S. Update on global epidemiology of viral hepatitis and preventive strategies. World J Clin Cases. 2018 Nov 6;6(13):589–599. https://doi.org/10.12998/wjcc.v6.i13.589JefferiesMRauffBRashidHLamTRafiqS. Update on global epidemiology of viral hepatitis and preventive strategies. World J Clin Cases.2018Nov 6;6(13):589–599. https://doi.org/10.12998/wjcc.v6.i13.58910.12998/wjcc.v6.i13.589623256330430114Search in Google Scholar

Jeng WJ, Sheen IS, Liaw YF. Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B. Clin Gastroenterol Hepatol. 2010 Jun;8(6):541–545. https://doi.org/10.1016/j.cgh.2010.02.023JengWJSheenISLiawYF. Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B. Clin Gastroenterol Hepatol.2010Jun;8(6):541–545. https://doi.org/10.1016/j.cgh.2010.02.02310.1016/j.cgh.2010.02.02320298811Search in Google Scholar

Kim H, Lee SA, Do SY, Kim BJ. Precore/core region mutations of hepatitis B virus related to clinical severity. World J Gastroenterol. 2016;22(17):4287–4296. https://doi.org/10.3748/wjg.v22.i17.4287KimHLeeSADoSYKimBJ. Precore/core region mutations of hepatitis B virus related to clinical severity. World J Gastroenterol.2016;22(17):4287–4296. https://doi.org/10.3748/wjg.v22.i17.428710.3748/wjg.v22.i17.4287485368627158197Search in Google Scholar

Kırdar S, Yaşa MH, Sayan M, Aydın N. [HBV pol/S gene mutations in chronic hepatitis B patients receiving nucleoside/nucleotide analogues treatment] (in Turkish). Mikrobiyol Bul. 2019;53(2):144–155. https://doi.org/10.5578/mb.67816KırdarSYaşaMHSayanMAydınN. [HBV pol/S gene mutations in chronic hepatitis B patients receiving nucleoside/nucleotide analogues treatment] (in Turkish). Mikrobiyol Bul.2019;53(2):144–155. https://doi.org/10.5578/mb.6781610.5578/mb.6781631130119Search in Google Scholar

Kmet Lunacek N, Poljak M, Meglic-Volkar J, Rajter M, Prah J, Lesnicar G, Selic Kurincic T, Baklan Z, Remec T, Pal E, et al. Epidemiological, virological and clinical characteristics of hepatitis B virus genotypes in chronically infected persons in Slovenia. Hepat Mon. 2017 Mar 04;17(3):e43838. https://doi.org/10.5812/hepatmon.43838Kmet LunacekNPoljakMMeglic-VolkarJRajterMPrahJLesnicarGSelic KurincicTBaklanZRemecTPalEEpidemiological, virological and clinical characteristics of hepatitis B virus genotypes in chronically infected persons in Slovenia. Hepat Mon.2017Mar 04;17(3):e43838. https://doi.org/10.5812/hepatmon.4383810.5812/hepatmon.43838Search in Google Scholar

Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, et al.; BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006 Mar 09;354(10):1011–1020. https://doi.org/10.1056/NEJMoa051287LaiCLShouvalDLokASChangTTCheinquerHGoodmanZDeHertoghDWilberRZinkRCCrossABEHoLD AI463027 Study Group.Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med.2006Mar 09;354(10):1011–1020. https://doi.org/10.1056/NEJMoa05128710.1056/NEJMoa05128716525138Search in Google Scholar

Liang TJ, Block TM, McMahon BJ, Ghany MG, Urban S, Guo JT, Locarnini S, Zoulim F, Chang KM, Lok AS. Present and future therapies of hepatitis B: from discovery to cure. Hepatology. 2015 Dec;62(6):1893–1908. https://doi.org/10.1002/hep.28025LiangTJBlockTMMcMahonBJGhanyMGUrbanSGuoJTLocarniniSZoulimFChangKMLokAS. Present and future therapies of hepatitis B: from discovery to cure. Hepatology.2015Dec;62(6):1893–1908. https://doi.org/10.1002/hep.2802510.1002/hep.28025468166826239691Search in Google Scholar

Lin CL, Yang HC, Kao JH. Hepatitis B virus: new therapeutic perspectives. Liver Int. 2016 Jan;36 Suppl 1:85–92. https://doi.org/10.1111/liv.13003LinCLYangHCKaoJH. Hepatitis B virus: new therapeutic perspectives.Liver Int.2016Jan;36Suppl 1:85–92. https://doi.org/10.1111/liv.1300310.1111/liv.1300326725903Search in Google Scholar

Liu YP, Yao CY. Rapid and quantitative detection of hepatitis B virus. World J Gastroenterol. 2015;21(42):11954–11963. https://doi.org/10.3748/wjg.v21.i42.11954LiuYPYaoCY. Rapid and quantitative detection of hepatitis B virus. World J Gastroenterol.2015;21(42):11954–11963. https://doi.org/10.3748/wjg.v21.i42.1195410.3748/wjg.v21.i42.11954464111726576084Search in Google Scholar

Lok AS, McMahon BJ, Brown RS Jr, Wong JB, Ahmed AT, Farah W, Almasri J, Alahdab F, Benkhadra K, Mouchli MA, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology. 2016 Jan;63(1):284–306. https://doi.org/10.1002/hep.28280LokASMcMahonBJBrownRSJrWongJBAhmedATFarahWAlmasriJAlahdabFBenkhadraKMouchliMAAntiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology.2016Jan;63(1):284–306. https://doi.org/10.1002/hep.2828010.1002/hep.2828026566246Search in Google Scholar

Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology. 2009 Sep;50(3):661–662. https://doi.org/10.1002/hep.23190LokASFMcMahonBJ. Chronic hepatitis B: Update 2009. Hepatology.2009Sep;50(3):661–662. https://doi.org/10.1002/hep.2319010.1002/hep.2319019714720Search in Google Scholar

Mahmood M, Anwar MA, Khanum A, Zaman N, Raza A. Distribution and clinical significance of hepatitis B virus genotypes in Pakistan. BMC Gastroenterol. 2016 Dec;16(1):104. https://doi.org/10.1186/s12876-016-0513-5MahmoodMAnwarMAKhanumAZamanNRazaA. Distribution and clinical significance of hepatitis B virus genotypes in Pakistan. BMC Gastroenterol.2016Dec;16(1):104. https://doi.org/10.1186/s12876-016-0513-510.1186/s12876-016-0513-5500216127565427Search in Google Scholar

Malagnino V, Fofana DB, Lacombe K, Gozlan J. Occult hepatitis B virus infection: An old entity with novel clinical involvements. IDSA. 2018;5(10):ofy227. https://doi.org/10.1093/ofid/ofy227MalagninoVFofanaDBLacombeKGozlanJ. Occult hepatitis B virus infection: An old entity with novel clinical involvements. IDSA.2018;5(10):ofy227. https://doi.org/10.1093/ofid/ofy22710.1093/ofid/ofy227618028530324127Search in Google Scholar

Manzoor S, Saalim M, Imran M, Resham S, Ashraf J. Hepatitis B virus therapy: what’s the future holding for us? World J Gastroenterol. 2015;21(44):12558–12575. https://doi.org/10.3748/wjg.v21.i44.12558ManzoorSSaalimMImranMReshamSAshrafJ. Hepatitis B virus therapy: what’s the future holding for us?World J Gastroenterol.2015;21(44):12558–12575. https://doi.org/10.3748/wjg.v21.i44.1255810.3748/wjg.v21.i44.12558465861026640332Search in Google Scholar

McNaughton AL, D’Arienzo V, Ansari MA, Lumley SF, Littlejohn M, Revill P, McKeating JA, Matthews PC. Insights from deep sequencing of the HBV genome-Inique,tiny, and misunderstood. Gastroenterology. 2019 Jan;156(2):384–399. https://doi.org/10.1053/j.gastro.2018.07.058McNaughtonALD’ArienzoVAnsariMALumleySFLittlejohnMRevillPMcKeatingJAMatthewsPC. Insights from deep sequencing of the HBV genome-Inique,tiny, and misunderstood. Gastroenterology.2019Jan;156(2):384–399. https://doi.org/10.1053/j.gastro.2018.07.05810.1053/j.gastro.2018.07.058634757130268787Search in Google Scholar

Mou Y, Athar MA, Wu Y, Xu Y, Wu J, Xu Z, Hayder Z, Khan S, Idrees M, Nasir MI, et al. Detection of anti-hepatitis B virus drug resistance mutations based o multicolor melting curve analysis. J Clin Microbiol. 2016 Nov;54(11):2661–2668. https://doi.org/10.1128/JCM.00439-16MouYAtharMAWuYXuYWuJXuZHayderZKhanSIdreesMNasirMIDetection of anti-hepatitis B virus drug resistance mutations based o multicolor melting curve analysis.J Clin Microbiol.2016Nov;54(11):2661–2668. https://doi.org/10.1128/JCM.00439-1610.1128/JCM.00439-16507854027535686Search in Google Scholar

Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Häussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 1996 May 30;334(22):1422–1427. https://doi.org/10.1056/NEJM199605303342202NiederauCHeintgesTLangeSGoldmannGNiederauCMMohrLHäussingerD. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med.1996May 30;334(22):1422–1427. https://doi.org/10.1056/NEJM19960530334220210.1056/NEJM1996053033422028618580Search in Google Scholar

Otero W, Parga J, Gastelbondo J. Serology of hepatitis B virus: multiple scenarios and multiple exams. Rev Col Gastroenterol. 2018; 33(4):404–413. http://doi.org/10.22516/25007440.327OteroWPargaJGastelbondoJ. Serology of hepatitis B virus: multiple scenarios and multiple exams. Rev Col Gastroenterol.2018; 33(4):404–413. http://doi.org/10.22516/25007440.32710.22516/25007440.327Search in Google Scholar

Paudel D, Suvedi S. Hepatitis B genotyping and clinical implications. London (UK): IntechOpen; 2019. http://doi.org/10.5772/intechopen.82492PaudelDSuvediS. Hepatitis B genotyping and clinical implications. London (UK): IntechOpen; 2019. http://doi.org/10.5772/intechopen.8249210.5772/intechopen.82492Search in Google Scholar

Pourkarim MR, Amini-Bavil-Olyaee S, Kurbanov F, Van Ranst M, Tacke F. Molecular identification of hepatitis B virus genotypes/subgenotypes: revised classification hurdles and updated resolutions. World J Gastroenterol. 2014;20(23):7152–7168. https://doi.org/10.3748/wjg.v20.i23.7152PourkarimMRAmini-Bavil-OlyaeeSKurbanovFVan RanstMTackeF. Molecular identification of hepatitis B virus genotypes/subgenotypes: revised classification hurdles and updated resolutions. World J Gastroenterol.2014;20(23):7152–7168. https://doi.org/10.3748/wjg.v20.i23.715210.3748/wjg.v20.i23.7152Search in Google Scholar

Rajoriya N, Combet C, Zoulim F, Janssen HLA. How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach? J Hepatol. 2017 Dec;67(6):1281–1297. https://doi.org/10.1016/j.jhep.2017.07.011RajoriyaNCombetCZoulimFJanssenHLA. How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?J Hepatol.2017Dec;67(6):1281–1297. https://doi.org/10.1016/j.jhep.2017.07.01110.1016/j.jhep.2017.07.011Search in Google Scholar

Razavi-Shearer D, Gamkrelidze I, Nguyen MH, Chen D-S, Van Damme P, Abbas Z, Abdulla M, Abou Rached A, Adda D, Aho I, et al.; Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018 Jun; 3(6):383–403. https://doi.org/10.1016/S2468-1253(18)30056-6Razavi-ShearerDGamkrelidzeINguyenMHChenD-SVan DammePAbbasZAbdullaMAbou RachedAAddaDAhoIPolaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol.2018Jun; 3(6):383–403. https://doi.org/10.1016/S2468-1253(18)30056-610.1016/S2468-1253(18)30056-6Search in Google Scholar

Roman S. Occult hepatitis B and other unexplored risk factors for hepatocellular carcinoma in Latin America. Ann Hepatol. 2018 Jul; 17(4):541–543. https://doi.org/10.5604/01.3001.0012.0914RomanS. Occult hepatitis B and other unexplored risk factors for hepatocellular carcinoma in Latin America. Ann Hepatol.2018Jul; 17(4):541–543. https://doi.org/10.5604/01.3001.0012.091410.5604/01.3001.0012.091429894289Search in Google Scholar

Rozanov M, Plikat U, Chappey C, Kochergin A, Tatusova T. A web-based genotyping resource for viral sequences. Nucleic Acids Res. 2004 Jul 01;32 Web Server:W654–W659. https://doi.org/10.1093/nar/gkh419RozanovMPlikatUChappeyCKocherginATatusovaT. A web-based genotyping resource for viral sequences.Nucleic Acids Res.2004Jul 01;32Web Server:W654–W659. https://doi.org/10.1093/nar/gkh41910.1093/nar/gkh41944155715215470Search in Google Scholar

Sayan M, Arikan A, Sanlidag T. Comparison of performance characteristics of DxN VERIS system versus Qiagen PCR for HBV genotype D and HCV genotype 1b quantification. Pol J Microbiol. 2019;68(1):139–143. https://doi.org/10.21307/pjm-2019-008SayanMArikanASanlidagT. Comparison of performance characteristics of DxN VERIS system versus Qiagen PCR for HBV genotype D and HCV genotype 1b quantification. Pol J Microbiol.2019;68(1):139–143. https://doi.org/10.21307/pjm-2019-00810.21307/pjm-2019-008725683531050262Search in Google Scholar

Scaglione SJ, Lok AS. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterol. 2012;142(6):1360–1368. https://doi.org/10.1053/j.gastro.2012.01.044ScaglioneSJLokAS. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterol.2012;142(6):1360–1368. https://doi.org/10.1053/j.gastro.2012.01.04410.1053/j.gastro.2012.01.04422537444Search in Google Scholar

Schreiber F. Phylogenetic sequence analysis. Methods course bioinformatics. 2007/08 [cited 2020]. Available from http://gobics.de/fabian/molbio_course/data/handout_phylogeny.pdfSchreiberF. Phylogenetic sequence analysis.Methods course bioinformatics.2007/08[cited 2020]. Available from http://gobics.de/fabian/molbio_course/data/handout_phylogeny.pdfSearch in Google Scholar

Shaha M, Sarker PK, Hossain MS, Das KC, Jahan M, Dey SK, Tabassum S, Hashem A, Salimullah M. Analysis of the complete genome of hepatitis B virus subgenotype C2 isolate NHB17965 from a HBV infected patient. F1000 Res. 2018;7:1023. https://doi.org/10.12688/f1000research.15090.3ShahaMSarkerPKHossainMSDasKCJahanMDeySKTabassumSHashemASalimullahM. Analysis of the complete genome of hepatitis B virus subgenotype C2 isolate NHB17965 from a HBV infected patient.F1000 Res.2018;7:1023. https://doi.org/10.12688/f1000research.15090.310.12688/f1000research.15090.3612438030228877Search in Google Scholar

Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr;67(4):1560–1599. https://doi.org/10.1002/hep.29800TerraultNALokASFMcMahonBJChangKMHwangJPJonasMMBrownRSJrBzowejNHWongJB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology.2018Apr;67(4):1560–1599. https://doi.org/10.1002/hep.2980010.1002/hep.29800597595829405329Search in Google Scholar

Than TT, Jo E, Todt D, Nguyen PH, Steinmann J, Steinmann E, Windisch MP. High environmental stability of Hepatitis B virus and inactivation requirements for chemical biocides. J Infect Dis. 2019 Mar 15;219(7):1044–1048. https://doi.org/10.1093/infdis/jiy620ThanTTJoETodtDNguyenPHSteinmannJSteinmannEWindischMP. High environmental stability of Hepatitis B virus and inactivation requirements for chemical biocides.J Infect Dis.2019Mar 15;219(7):1044–1048. https://doi.org/10.1093/infdis/jiy62010.1093/infdis/jiy620642016530358855Search in Google Scholar

Tsuge M, Murakami E, Imamura M, Abe H, Miki D, Hiraga M, Takahashi S, et al. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of NA treatments in CHB patients. J Gastroenterol. 2013;48:1188–1204. https://doi.org/10.1007/s00535-012-0737-2TsugeMMurakamiEImamuraMAbeHMikiDHiragaMTakahashiSSerum HBV RNA and HBeAg are useful markers for the safe discontinuation of NA treatments in CHB patients.J Gastroenterol.2013;48:1188–1204. https://doi.org/10.1007/s00535-012-0737-210.1007/s00535-012-0737-223397114Search in Google Scholar

Van Damme P. Long-term protection after hepatitis B vaccine. J Infect Dis. 2016 Jul 01;214(1):1–3. https://doi.org/10.1093/infdis/jiv750Van DammeP. Long-term protection after hepatitis B vaccine.J Infect Dis.2016Jul 01;214(1):1–3. https://doi.org/10.1093/infdis/jiv75010.1093/infdis/jiv75026802140Search in Google Scholar

Villar LM, Cruz HM, Barbosa JR, Bezerra CS, Portilho MM, Scalioni LP. Update on hepatitis B and C virus diagnosis. World J Virol. 2015;4(4):323–342. https://doi.org/10.5501/wjv.v4.i4.323VillarLMCruzHMBarbosaJRBezerraCSPortilhoMMScalioniLP. Update on hepatitis B and C virus diagnosis. World J Virol.2015;4(4):323–342. https://doi.org/10.5501/wjv.v4.i4.32310.5501/wjv.v4.i4.323464122526568915Search in Google Scholar

Wang J, Zhang P, Zeng J, Du P, Zheng X, Ye X, Zhu W, Fu Y, Candotti D, Allain JP, et al. Occurrence of occult hepatitis B virus infection associated with envelope protein mutations according to anti-HBs carriage in blood donors. Int J Infect Dis. 2020 Mar;92:38–45. https://doi.org/10.1016/j.ijid.2019.12.026WangJZhangPZengJDuPZhengXYeXZhuWFuYCandottiDAllainJPOccurrence of occult hepatitis B virus infection associated with envelope protein mutations according to anti-HBs carriage in blood donors. Int J Infect Dis.2020Mar;92:38–45. https://doi.org/10.1016/j.ijid.2019.12.02610.1016/j.ijid.2019.12.02631877352Search in Google Scholar

Wang W, Shu Y, Bao H, Zhao W, Wang W, Wang Q, Lei X, Cui D, Yan Z. Genotypes and hot spot mutations of hepatitis B virus in northwest Chinese population and its correlation with disease progression. BioMed Res Int. 2019 Dec 10;2019:1–9. https://doi.org/10.1155/2019/3890962WangWShuYBaoHZhaoWWangWWangQLeiXCuiDYanZ. Genotypes and hot spot mutations of hepatitis B virus in northwest Chinese population and its correlation with disease progression.BioMed Res Int.2019Dec 10;2019:1–9. https://doi.org/10.1155/2019/389096210.1155/2019/3890962692579731886206Search in Google Scholar

Wei W, Wu Q, Zhou J, Kong Y, You H. A better antiviral efficacy found in nucleos(t)ide analog (NA) combinations with interferon therapy than NA monotherapy for HBeAg positive chronic hepatitis B:A meta-analysis. Int J Environ Res Public Health. 2015 Aug 21; 12(8):10039–10055. https://doi.org/10.3390/ijerph120810039WeiWWuQZhouJKongYYouH. A better antiviral efficacy found in nucleos(t)ide analog (NA) combinations with interferon therapy than NA monotherapy for HBeAg positive chronic hepatitis B:A meta-analysis. Int J Environ Res Public Health.2015Aug 21; 12(8):10039–10055. https://doi.org/10.3390/ijerph12081003910.3390/ijerph120810039455532726308024Search in Google Scholar

WHO. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection [Internet]. Geneva (Switzerland): World Health Organization; 2015 [cited 2020 Mar]. Available from https://www.ncbi.nlm.nih.gov/books/NBK305553/pdf/Bookshelf_ NBK305553.pdfWHO. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection [Internet]. Geneva (Switzerland): World Health Organization; 2015[cited 2020 Mar]. Available from https://www.ncbi.nlm.nih.gov/books/NBK305553/pdf/Bookshelf_ NBK305553.pdfSearch in Google Scholar

WHO. Global Health Section Strategy on Viral Hepatitis 2016–2021 [Internet]. Geneva (Switzerland): World Health Organization; 2016 [cited 2020 Jun]. Available from https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf;jsessionid=BB8 238CF4BF67C1B4A8A93329842962F?sequence=1WHO. Global Health Section Strategy on Viral Hepatitis 2016–2021 [Internet]. Geneva (Switzerland): World Health Organization; 2016[cited 2020 Jun]. Available from https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf;jsessionid=BB8 238CF4BF67C1B4A8A93329842962F?sequence=1Search in Google Scholar

WHO. Hepatitis B vaccination has dramatically reduced infection rates among children in Europe, but more is needed to achieve elimination [Internet]. Geneva (Switzerland): World Health Organization; 2017a [cited 2020 Mar]. Available from http://www.euro. who.int/en/health-topics/communicable-diseases/hepatitis/news/news/2017/04/hepatitis-b-vaccination-has-dramatically-reduced-infection-rates-among-children-in-europe,-but-more-is-needed-to-achieve-eliminationWHO. Hepatitis B vaccination has dramatically reduced infection rates among children in Europe, but more is needed to achieve elimination [Internet]. Geneva (Switzerland): World Health Organization; 2017a[cited 2020 Mar]. Available from http://www.euro. who.int/en/health-topics/communicable-diseases/hepatitis/news/news/2017/04/hepatitis-b-vaccination-has-dramatically-reduced-infection-rates-among-children-in-europe,-but-more-is-needed-to-achieve-eliminationSearch in Google Scholar

WHO. Guidelines on hepatitis B and C testing [Internet]. Geneva (Switzerland): World Health Organization; 2017b [cited 2020 Jun]. Available from https://apps.who.int/iris/bitstream/handle/10665/254621/9789241549981-eng.pdf;jsessionid=A0864CBC8CC4C869 B57151EFE7359170?sequence=1WHO. Guidelines on hepatitis B and C testing [Internet]. Geneva (Switzerland): World Health Organization; 2017b[cited 2020 Jun]. Available from https://apps.who.int/iris/bitstream/handle/10665/254621/9789241549981-eng.pdf;jsessionid=A0864CBC8CC4C869 B57151EFE7359170?sequence=1Search in Google Scholar

WHO. Hepatitis B Key Facts [Internet]. Geneva (Switzerland): World Health Organization; 2019a [cited 2020 Jul]. Available from https://www.who.int/news-room/fact-sheets/detail/hepatitis-bWHO. Hepatitis B Key Facts [Internet]. Geneva (Switzerland): World Health Organization; 2019a[cited 2020 Jul]. Available from https://www.who.int/news-room/fact-sheets/detail/hepatitis-bSearch in Google Scholar

WHO. Hepatitis B in the WHO European region [Internet]. Geneva (Switzerland): World Health Organization; 2019b [cited 2020 Jul]. Available from http://www.euro.who.int/__data/assets/pdf_file/0007/377251/Fact-Sheet-Hepatitis-B_2019-ENG.pdf?ua=1WHO. Hepatitis B in the WHO European region [Internet]. Geneva (Switzerland): World Health Organization; 2019b[cited 2020 Jul]. Available from http://www.euro.who.int/__data/assets/pdf_file/0007/377251/Fact-Sheet-Hepatitis-B_2019-ENG.pdf?ua=1Search in Google Scholar

WHO. Hepatitis D [Internet]. Geneva (Switzerland): World Health Organization; 2020 [cited 2020 Jul]. Available from https://www. who.int/news-room/fact-sheets/detail/hepatitis-dWHO. Hepatitis D [Internet]. Geneva (Switzerland): World Health Organization; 2020[cited 2020 Jul]. Available from https://www. who.int/news-room/fact-sheets/detail/hepatitis-dSearch in Google Scholar

Wu IC, Liu WC, Chang TT. Applications of next generation sequencing analysis for the detection of hepatocellular carcinoma associated hepatitis B virus mutations. J Biomed Sci. 2018;25(51):1–12. https://doi.org/10.1186/s12929-018-0442-4WuICLiuWCChangTT. Applications of next generation sequencing analysis for the detection of hepatocellular carcinoma associated hepatitis B virus mutations.J Biomed Sci.2018;25(51):1–12. https://doi.org/10.1186/s12929-018-0442-410.1186/s12929-018-0442-4598482329859540Search in Google Scholar